CooperSurgical's attack surface spans 600+ medical devices, clinical data pipelines handling sensitive fertility and reproductive health records, and manufacturing operations across the U.S., Costa Rica, and Europe. The company operates in a threat landscape where protected health information (PHI) is the primary target - IVF patient records, reproductive genetics data, and assisted reproductive technology (ART) workflows all carry elevated regulatory and privacy stakes under HIPAA and international equivalents.
Headquartered in Trumbull, Connecticut, CooperSurgical has been building its women's health and fertility portfolio for nearly 35 years, now serving more than 100 countries. The product line spans reproductive care devices, IVF and reproductive genetics solutions, and birth-related medical devices. That means security teams are working across connected medical device firmware, cloud-based clinical platforms, and global manufacturing infrastructure simultaneously.
For cybersecurity practitioners, the draw is specificity: this is a regulated healthcare environment where the data is genuinely sensitive, the device fleet is large and clinically consequential, and the regulatory surface - FDA, HIPAA, GDPR across European operations - dictates real engineering constraints. The company describes itself as purpose-driven with a restless approach to problem-solving, which in practice means security work that directly touches patient outcomes across fertility, birth, and family care.
